Dc-sign antibody drug conjugates
AssigneeNovartis AG
InventorsLisa BARNETT, Steven BENDER, Alex Cortez, Sarah COX, Jonathan DEANE, Scott Martin GLASER, Ben WEN, Tom Yao-Hsiang WU
Life of this patent
Estimating the term…
Abstract
Provided herein are antibodies to DC-SIGN, conjugates of DC-SiGN antibodies, and DC-SiGN antibody fusion proteins and the use of such antibodies, conjugates, and fusion proteins for the treatment of diseases such as cancer.
Claims26
An antibody or antigen binding fragment thereof that binds to human DC-SIGN protein, wherein the antibody or antigen binding fragment thereof has a higher affinity to human DC-SIGN than human L-SIGN.
2-17. (canceled)
A conjugate comprising an anti-DC-SIGN antibody or an antigen binding fragment thereof, coupled to drug moiety (D), wherein D is optionally coupled via a linker (L), wherein the linker optionally comprises one or more cleavage elements.
(canceled)
34-36. (canceled)
39-49. (canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.